We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
It’s getting crowded on the cell therapy bandwagon — and it won’t be able to hold many more passengers, according to a market analysis by GlobalData. Read More
Merck hit its second roadblock in a week, following the failure of its Lynparza trial with negative results in KEYNOTE-412, a phase 3 trial of Keytruda (pembrolizumab) in patients with unresected locally advanced head and neck squamous cell carcinoma. Read More
Merck is halting its phase 3 study of Lynparza (olaparib) in advanced colorectal cancer after a midstream futility analysis found no survival benefit associated with the drug. Read More
Amarin’s fish oil-based heart drug Vascepa (icosapent ethyl) may not have been as effective as initially thought, according to a new analysis in the American Heart Association journal Circulation. Read More
A postsurgical chemotherapy regimen of Roche’s Perjeta (pertuzumab) plus Herceptin (trastuzumab) and chemotherapy cut the risk of death by 28 percent compared to Herceptin and chemo alone in patients with lymph node-positive, hormone receptor-positive (HER-2) breast cancer. Read More
Eli Lilly has teamed up with China-based Triastek to use three-dimensional (3D) drug printing for targeted release in certain parts of the gastrointestinal (GI) tract. Read More
Sanofi and Regeneron’s Dupixent (dupilumab) continues its march against a host of chronic inflammatory diseases, posting positive phase 3 data in children with eosinophilic esophagitis, a chronic inflammation of the esophagus associated with acid reflux, gastrointestinal problems, difficulty eating and failure to thrive. Read More
More encouraging news about potential hemophilia therapeutics emerged this week, with Sanofi announcing “unprecedented” phase 3 data on efanesoctocog alfa, a bioengineered clotting factor, and fitusiran, an RNA therapeutic that lowers antithrombin. Read More
Xeljanz, a Janus kinase inhibitor, is FDA-approved for several indications, including for patients with moderate-to-severe active ulcerative colitis. Read More